Open AccessFeasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited‐disease small cell lung cancer
Author(s) -
Sekine Ikuo,
Sumi Minako,
Satouchi Miyako,
Tsujino Kayoko,
Nishio Makoto,
Kozuka Takuyo,
Niho Seiji,
Nihei Keiji,
Yamamoto Nobuyuki,
Harada Hideyuki,
Ishikura Satoshi,
Tamura Tomohide
Publication year - 2016
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12875
Subject(s) - medicine , neutropenia , chemoradiotherapy , gastroenterology , anemia , lung cancer , cisplatin , febrile neutropenia , etoposide , granulocyte colony stimulating factor , chemotherapy , radiation therapy , surgery
To evaluate the feasibility of amrubicin plus cisplatin ( AP ) following chemoradiotherapy for limited‐disease small‐cell lung cancer, chemo‐naïve patients aged 20–70 years with a performance status of 0 or 1 and normal organ functions were treated with etoposide 100 mg/m 2 on days 1–3, cisplatin 80 mg/m 2 on day 1 and concurrent thoracic radiotherapy at 45 Gy/30 fractions ( EP ‐ TRT ), followed by three cycles of amrubicin 40 mg/m 2 on days 1–3 and cisplatin 60 mg/m 2 on day 1 every 3 weeks. The EP ‐ TRT could be completed in 21 patients (15 male and 6 female patients with a median age of 62 years). Of these, 2, 1 and 18 (86%) patients received one, two and three cycles of AP , respectively. Sixteen (76%) patients required granulocyte‐colony stimulating factor (G‐ CSF ) support. Grade 3/4 neutropenia occurred in all patients. Grade 3 febrile neutropenia was observed in 9 patients, lasting for 1 day in 5 patients. The incidences of grade 3/4 thrombocytopenia and anemia were 43 and 24%, respectively. Grade 3 infection and anorexia occurred in 2 and 3 patients, respectively. The response rate was 95%. The median (95% confidence interval [ CI ]) progression‐free survival ( PFS ) was 41.9 (0–102) months, and the 5‐year PFS rate ( CI ) was 41.9% (20.4–63.4%). The median overall survival ( OS ) has not been reached yet, and the 5‐year OS rate ( CI ) was 57.8% (35.2–80.4%). In conclusion, EP ‐ TRT followed by AP therapy was well‐tolerated, although a large number of patients required G‐ CSF support.